New to peptides? Start with the foundations ->
Why people use Semaglutide for Type 2 diabetes
Ozempic for diabetes. What's the typical A1C drop? The short answer: yes, this is one of the more-discussed uses for Semaglutide - but the evidence quality and the right protocol depend on what you're actually trying to fix.
This page covers what's known, what's not, and what the editorial take is for normal humans considering Semaglutide for Type 2 diabetes.
What the evidence says
Evidence tier: FDA-approved. FDA-approved with multiple randomized trials behind it. The strongest evidence tier in this matrix.
- SUSTAIN trials showed A1C reductions of 1.5-1.8 percentage points.
- FDA-approved as Ozempic for adult Type 2 diabetes.
- Often first-line after metformin in newer treatment guidelines.
Protocol notes
Standard Ozempic titration: 0.25mg -> 0.5mg -> 1mg -> 2mg max.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full Semaglutide directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine